SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

GRAIL Inc.

GRAIL Inc. is experiencing a sharp sell-off, down significantly after an NHS trial for its Galleri multi-cancer early detection test reportedly missed a primary endpoint; however, community discussion emphasizes this as an overreaction, pointing to strong Q4 revenue and EPS beats, a solid cash runway, and the test's proven ability to detect early-stage cancers, fueling calls to buy the dip and anticipate a potential short squeeze.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is trending amidst investor anticipation for its conference and financial results, fueled by strong underlying sales growth from its products and the Alani Nu integration. Nevertheless, community sentiment is sharply divided, with ongoing discussions scrutinizing management's communication and the implications of Pepsi's deepening strategic involvement, including persistent buyout speculation.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is actively discussed following recent announcements of a $100 million public stock offering alongside a separate $100 million non-dilutive royalty financing deal, generating a split community reaction between concerns over dilution and recognition of strategic backing from a specialized biotech investor. Further interest surrounds the company's upcoming data presentation on its glioblastoma program at a key industry summit, with investors also awaiting anticipated updates for its broader oncology pipeline.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending on the heels of robust 2025 revenue, a significant patent extension for its key drugs until 2042, and the launch of a Phase 3 trial for IBSRELA in Chronic Idiopathic Constipation. The community is actively discussing these catalysts alongside heightened speculation regarding a potential acquisition and multiple analyst price target increases, despite some frustration over perceived stock manipulation.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is trending following investor concerns about its path to profitability and weak guidance shared during its recent earnings call, sparking community debate over the 'buy now, pay never' business model amidst significant stock price drops.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont Corp. is actively discussed after exceeding Q4 earnings and revenue expectations, fueled by strong financial performance and record free cash flow. However, a cautious 2026 production outlook is creating community debate, with many questioning the stock's current valuation given the continued strength in gold prices.

Sprouts Farmers Market, Inc. engages in the operation of healthy grocery stores. The firm specializes in fresh, natural and organic products. Its products include fresh produce, bulk foods, vitamins and supplements, grocery, meat and seafood, deli, bakery, dairy, frozen foods, body care and natural household items. The company was founded by Stan Boney, Shon Alexander Boney, and Kevin K. Easler on July 11, 2002 and is headquartered in Phoenix, AZ.

Sprouts Farmers Market Inc

Sprouts Farmers Market is trending due to a significant stock decline after its Q3 earnings report, which, despite an EPS beat, included a revenue miss and cautious Q4 guidance attributed to softer consumer demand. The community is sharply divided, with bulls emphasizing strong fundamentals, a substantial share repurchase program, and store expansion as a buying opportunity, while bears highlight slowing comparable sales and valuation concerns.

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its products include Tandem Mobi System and t:slim X2 Insulin Pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.

Tandem Diabetes Care Inc

Tandem Diabetes Care is trending due to recent strategic partnerships with Abbott and Eli Lilly for integrated diabetes solutions and new Control-IQ+ technology, which are creating bullish sentiment amidst a volatile period marked by a voluntary medical device correction and mixed financial guidance. The community is sharply divided between those anticipating a major rebound and potential acquisition, and others fearing continued competitive and operational challenges in the diabetes market.

Akamai Technologies, Inc. engages in the provision of cloud services for delivering, optimizing, and securing content and business applications over the Internet. Its products include security, web performance, media delivery, and network operator. The company was founded by Frank T. Leighton, Jonathan Seelig, Randall S. Kaplan, and Daniel M. Lewin on August 20, 1998 and is headquartered in Cambridge, MA.

Akamai Technologies Inc

Akamai Technologies is trending following a mixed earnings report, where strong Q4 performance and growth in security and cloud solutions were eclipsed by lower-than-expected forward guidance, fueling community debate on its AI edge computing pivot amidst a competitive landscape.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin is trending due to circulating rumors of a strategic OpenAI partnership for monetizing ChatGPT, fueling a robust rebound and intense debate among investors. This comes as the company navigates a competitive ad-tech landscape, with many bulls citing strong underlying earnings as a reason to buy the dip.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$TSLA 23 straight days of nothing since Elon&#39;s purchase. Now earnings coming up and they are making the chart look absolutely disgusting in the process. Every we test 425.7, get scary and then hold. Over this shit.

James Jones

ARSENEPAL WRIGHT

derrick williams

Brendan McIlvene

Matija Kraševec

Alex Smith

Alex More

StockTwits for iOS

StockTwits Web

 23 straight days of nothing since Elon's purchase. Now earnings coming up and they are making the chart look absolutely disgusting in the process. Every we test 425.7, get scary and then hold. Over this shit.